{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:51:51Z","timestamp":1771663911445,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.breast.2024.103777","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T05:21:21Z","timestamp":1720934481000},"page":"103777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["The impact of extensive intraductal component (EIC) on the genomic risk of recurrence in early hormone receptor positive breast cancer"],"prefix":"10.1016","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5762-5621","authenticated-orcid":false,"given":"Yael","family":"Bar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kfir","family":"Bar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didi","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith Ben-","family":"Dror","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meishar","family":"Shahoha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shir","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shlomit Strulov","family":"Shachar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahuva","family":"Weiss-Meilik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nachum","family":"Dershowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ido","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Sonnenblick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2024.103777_bib1","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.3390\/cancers13174287","article-title":"Breast cancer\u2014epidemiology, risk factors, classification, prognostic markers, and current treatment strategies\u2014an updated review","volume":"13","author":"\u0141ukasiewicz","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.breast.2024.103777_bib2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41416-019-0478-6","article-title":"Ductal carcinoma in situ: to treat or not to treat, that is the question","volume":"121","author":"on behalf of the Precision team","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.breast.2024.103777_bib3","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/jnci\/djy220","article-title":"Cancer outcomes in DCIS patients without locoregional treatment","volume":"111","author":"Ryser","year":"2019","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.breast.2024.103777_bib4","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ejso.2017.12.007","article-title":"Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ","volume":"44","author":"Maxwell","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.breast.2024.103777_bib5","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/1097-0142(19951001)76:7<1197::AID-CNCR2820760715>3.0.CO;2-0","article-title":"Continued local recurrence of carcinoma 15\u201325 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy","volume":"76","author":"Page","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2024.103777_bib6","doi-asserted-by":"crossref","first-page":"484","DOI":"10.21037\/atm.2019.08.16","article-title":"The prognostic significance of co-existence ductal carcinoma in situ in invasive ductal breast cancer: a large population-based study and a matched case-control analysis","volume":"7","author":"Chen","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.breast.2024.103777_bib7","doi-asserted-by":"crossref","first-page":"9934","DOI":"10.1038\/s41598-019-46309-2","article-title":"Overall survival is improved when DCIS accompanies invasive breast cancer","volume":"9","author":"Kole","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.breast.2024.103777_bib8","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2147\/CMAR.S154656","article-title":"Prognostic value of ductal carcinoma in situ component in invasive ductal carcinoma of the breast: a Surveillance, Epidemiology, and End Results database analysis","volume":"10","author":"Wu","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.breast.2024.103777_bib9","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/1097-0142(19840301)53:5<1049::AID-CNCR2820530506>3.0.CO;2-O","article-title":"Pathologic predictors of early local recurrence in stage I and II breast cancer treated by primary radiation therapy","volume":"53","author":"Schnitt","year":"1984","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2024.103777_bib10","unstructured":"Cedolini, C. et al. Impact of the presence and quantity of ductal carcinoma in situ component on the outcome of invasive breast cancer."},{"key":"10.1016\/j.breast.2024.103777_bib11","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/sj.bjc.6605655","article-title":"Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer","volume":"102","author":"Wong","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.breast.2024.103777_bib12","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1007\/s12032-011-0082-y","article-title":"Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer","volume":"29","author":"Wong","year":"2012","journal-title":"Med Oncol"},{"key":"10.1016\/j.breast.2024.103777_bib13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12282-011-0330-1","article-title":"Influence of the in situ component in 389 infiltrating ductal breast carcinomas","volume":"20","author":"Carabias-Meseguer","year":"2013","journal-title":"Breast Cancer"},{"key":"10.1016\/j.breast.2024.103777_bib14","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1002\/(SICI)1097-0142(19961101)78:9<1921::AID-CNCR12>3.0.CO;2-#","article-title":"Pathologic margin involvement and the risk of recurrence in patients treated with breast\u2010conserving therapy","volume":"78","author":"Gage","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2024.103777_bib15","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1200\/JCO.2017.74.0472","article-title":"Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American society of clinical oncology clinical practice guideline focused update","volume":"35","author":"Krop","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2024.103777_bib16","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1904819","article-title":"Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer","volume":"380","author":"Sparano","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2024.103777_bib17","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2024.103777_bib18","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","article-title":"Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor\u2013positive breast cancer","volume":"24","author":"Paik","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2024.103777_bib19","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","article-title":"Prospective validation of a 21-gene expression assay in breast cancer","volume":"373","author":"Sparano","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2024.103777_bib20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2024.103777_bib21","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1001\/jamaoncol.2019.4794","article-title":"Clinical outcomes in early breast cancer with a high 21-gene recurrence score of 26 to 100 assigned to adjuvant chemotherapy plus endocrine therapy: a secondary analysis of the TAILORx randomized clinical trial","volume":"6","author":"Sparano","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2024.103777_bib22","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1200\/JCO.2015.63.5383","article-title":"West German study group phase III PlanB trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment","volume":"34","author":"Gluz","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2024.103777_bib23","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2024.103777_bib24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41523-017-0033-7","article-title":"Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry","volume":"3","author":"Stemmer","year":"2017","journal-title":"Npj Breast Cancer"},{"key":"10.1016\/j.breast.2024.103777_bib25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","article-title":"Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial","volume":"11","author":"Albain","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2024.103777_bib26","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/s41416-020-01212-w","article-title":"Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component","volume":"124","author":"Zeng","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.breast.2024.103777_bib27","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1200\/JCO.2005.06.178","article-title":"Population-based validation of the prognostic model ADJUVANT! For early breast cancer","volume":"23","author":"Olivotto","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2024.103777_bib28","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1470-2045(09)70254-2","article-title":"Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study","volume":"10","author":"Mook","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2024.103777_bib29","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2024.103777_bib30","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.breast.2021.09.002","article-title":"The impact of tumor detection method on genomic and clinical risk and chemotherapy recommendation in early hormone receptor positive breast cancer","volume":"60","author":"Bar","year":"2021","journal-title":"Breast"},{"key":"10.1016\/j.breast.2024.103777_bib31","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1007\/s00432-019-02930-2","article-title":"Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC\/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes","volume":"145","author":"Goh","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.breast.2024.103777_bib32","volume":"99","author":"Guan","year":"2020","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.breast.2024.103777_bib33","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/1471-2407-12-306","article-title":"The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients","volume":"12","author":"Medrek","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.breast.2024.103777_bib34","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/his.13956","article-title":"MMP11 expression in intratumoral inflammatory cells in breast cancer","volume":"75","author":"Eiro","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.breast.2024.103777_bib35","doi-asserted-by":"crossref","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","article-title":"NCCN Guidelines\u00ae insights: breast cancer, version 4.2023: featured updates to the NCCN guidelines","volume":"21","author":"Gradishar","year":"2023","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.breast.2024.103777_bib36","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2020","author":"Loibl","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2024.103777_bib37","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ijsu.2019.01.016","article-title":"Influence of ductal carcinoma in situ on the outcome of invasive breast cancer. A prospective cohort study","volume":"63","author":"Lopez Gordo","year":"2019","journal-title":"Int J Surg"},{"key":"10.1016\/j.breast.2024.103777_bib38","doi-asserted-by":"crossref","first-page":"558","DOI":"10.5858\/arpa.2012-0198-RA","article-title":"Understanding sources of bias in diagnostic accuracy studies","volume":"137","author":"Schmidt","year":"2013","journal-title":"Arch Pathol Lab Med"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977624001085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977624001085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T01:32:46Z","timestamp":1726104766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977624001085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":38,"alternative-id":["S0960977624001085"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2024.103777","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of extensive intraductal component (EIC) on the genomic risk of recurrence in early hormone receptor positive breast cancer","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2024.103777","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103777"}}